Skip to content

Cannabis: all studies

Page 211 of 288: studies 2,101 to 2,110 of 2,874, newest first. Back to the cannabis overview

Research

Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distribution

Canadian Journal of Public Health March 19, 2026 Jenna Matsukubo, Erik Loewen Friesen, Rachael MacDonald-Spracklin et al. 1 citation

IntroductionThe use of psychedelics has increased in Canada in recent years. Although non-medical psilocybin use is prohibited under the Controlled Drugs and Substances Act, we previously documented the emergence of grey-market brick-and-mortar psilocybin retailers. This study examined changes in the number, composition, and geographic distribution of Canadian psilocybin retail stores between...

Do Psychedelics Mimic Psychosis? Perspectives on Similarities and Differences from Individuals with Lived Experience of Psychosis and Psychedelics

International Journal of Mental Health and Addiction March 17, 2026 Haley Maria Dourron, Melissa Bradley, Heith Copes et al.

Abstract Despite a long-standing interest in the potential similarities between psychedelic and psychotic experiences, no recent research has systematically explored the subjective overlap between these states in individuals who have experienced both. To provide rich accounts of potential overlaps and distinctions, we conducted semi-structured interviews with 19 individuals diagnosed with...

DOI: 10.1007/s11469-026-01649-9 (opens in new tab) Full text (opens in new tab) Psychosis Thematic analysis Lived experience Meaning existential +10

Recreational drug poisonings reported to six European poison centres from 2021 to 2024

Clinical Toxicology March 4, 2026 Laura Hondebrink, Katrin Faber, Aza Kader et al. 1 citation

INTRODUCTION: Recreational drug poisonings pose a growing public health concern. European-level data remain limited, although poison centres are well placed to monitor related health incidents. This study analysed temporal trends in recreational drug poisonings reported to six European poison centres. METHODS: Aggregated retrospective data were collected over four years (2021-2024) from poison...

DOI: 10.1080/15563650.2026.2628073 (opens in new tab) Recreational use Public health Poison control Recreational drug use +6

The Endocannabinoid System in PTSD: Molecular Targets for Modulating Fear and Anxiety.

Pharmacopsychiatry March 2026 Stanley Lyndon

Fear and anxiety perform essential protective roles, yet when they become dysregulated, they can trap trauma survivors in persistent hypervigilance and distress. Post-traumatic stress disorder (PTSD) manifests as intrusive memories, avoidance, and heightened arousal long after the precipitating event. Although current pharmacotherapies - including selective serotonin reuptake inhibitors,...

Perceived Availability of Lysergic Acid Diethylamide in the United States from 2015 to 2019

Psychedelic Medicine March 1, 2026 Brian S. Barnett, Akhil Anand, Elizabeth N. Dewey et al.

Objective: While data on perceived availability of lysergic acid diethylamide (LSD) [paLSD] are collected annually in the United States, detailed investigations of recent trends in paLSD have not been published. Therefore, we sought to explore this topic. Method: Data were sourced from the 2015–2019 National Survey on Drug Use and Health (NSDUH) administrations. To identify factors associated...

Epidemiology of Hallucinogen Microdosing Among Young Adults in the United States: A National Study

Drug and Alcohol Review February 26, 2026 Katherine M Keyes, Yvonne Terry-Mcelrath, Megan E. Patrick

INTRODUCTION: This paper aimed to determine the prevalence, demographic correlates and co-occurring substance use patterns of hallucinogen microdosing among young adults in the United States. METHODS: Design: Cross-sectional analysis of data from a nationally-representative cohort study collected in 2022-2023. SETTING: United States. PARTICIPANTS: Sample of 3094 young adults aged 19-30 years in...

DOI: 10.1111/dar.70133 (opens in new tab) Young adult Context archaeology Epidemiology Drug +3

Cannabinoids

February 17, 2026 Linda A. Parker

The mysteries of the brain’s own cannabinoid system exposed and explained. Though cannabis has been used, for pain or pleasure, for over 4000 years, only lately have we learned, first, what makes it work and, more recently, how. Unraveling the mystery of the human brain’s special relationship with a psychoactive chemical derived from a plant—tetrahydrocannabinol, or THC,...

India's Unique Legal Framework for Psilocybin Mushroom Research: An Unprecedented Opportunity in Psychiatric Therapeutics.

Indian Journal of Psychological Medicine February 5, 2026 Ashlyn Tom, B. Sai Chaitanya Reddy, Manik Inder Singh Sethi et al.

The “entourage effect,” well-documented in cannabis research, remains a hypothesis requiring validation in psilocybin mushrooms. Whether the complex interplay among multiple bioactive compounds (including psilocybin, psilocin, baeocystin, norbaeocystin, aeruginascin, and various alkaloids) produces synergistic effects distinct from those of isolated psilocybin remains a critical empirical...

Acute and long-term psychiatric consequences of synthetic cannabinoids and related novel psychoactive substances: A systematic review.

Psychiatry Research February 1, 2026 Valerio Ricci, Stefania Chiappini, Giovanni Martinotti et al.

BACKGROUND Novel psychoactive substances (NPS) represent an evolving public health threat, yet evidence on their acute and long-term psychiatric consequences remains limited. OBJECTIVE To systematically review psychiatric and neurological consequences of NPS use across the full clinical spectrum, with primary focus on synthetic cannabinoids and related compounds, and to characterize...